Analyst Ratings for Roivant Sciences
Portfolio Pulse from Benzinga Insights
Roivant Sciences (NASDAQ:ROIV) has received positive analyst ratings in the last quarter, with 5 bullish and 2 somewhat bullish ratings out of 7. The average price target is $16.57, representing a significant upside from the current price of $9.99. This target has increased by 5.74% from the previous target of $15.67. Analysts derive their ratings from various sources, including company data and insider information.
December 12, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roivant Sciences has received overwhelmingly positive ratings from analysts, with a current average price target of $16.57, suggesting a significant potential upside from the current price of $9.99.
The positive analyst ratings and the increased price target suggest that the market's perception of Roivant Sciences is improving. This optimism is likely to influence investor sentiment and could lead to a short-term increase in ROIV's stock price, as the market often reacts to analyst ratings and price targets. The unanimous bullish sentiment and the substantial upside implied by the target price reinforce the potential for a positive impact on the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100